Education
About Us
Working with TipRanks
Follow Us
Atai Beckley N.V. (ATAI)
NASDAQ:ATAI
ATAI Stock Chart & Stats
$3.69
-$0.11(-6.29%)
At close: 4:00 PM EST
$3.69
-$0.11(-6.29%)
Day’s Range― - ―
52-Week Range$1.15 - $6.75
Previous CloseN/A
Volume1.44M
Average Volume (3M)4.05M
Market Cap
$1.34B
Enterprise Value$668.58M
Total Cash (Recent Filing)$114.61M
Total Debt (Recent Filing)$2.96M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Mar 26, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding363,214,600
10 Day Avg. Volume5,094,891
30 Day Avg. Volume4,053,470
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.83
Price to Sales (P/S)691.60
P/FCF Ratio-2.58
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue221.53
Enterprise Value/Gross Profit-85.50
Enterprise Value/Ebitda-4.61
Forecast
1Y Price Target
$14.71Price Target Upside298.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$454.55K
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPositive Phase 2a results for EMP-01 showing meaningful improvement on social anxiety measures versus placebo provide clinical proof of concept that could increase confidence in the program’s therapeutic potential.
Clinical Trial DesignRegulatory alignment on the Phase 3 protocol establishes a pivotal study framework with a true placebo arm, which could improve result credibility and attract investor interest if trial execution progresses smoothly.
Commercial PathwayShort half-lives and demonstrated rapid, sustained effects for lead assets support a clinic-based treatment model similar to an existing approved therapy, offering a practical commercial route for treating resistant depression.
Bears Say
Market Sentiment And Financing RiskNegative sector commentary and broader market weakness have pressured the stock, while the potential for equity raises and unresolved regulatory scheduling for psychedelic therapies increases downside risk for investors.
Safety ConcernsMultiple discontinuations for blood pressure increases and an event involving suicidal ideation create safety signals that could complicate regulatory reviews and raise monitoring requirements in future trials.
Valuation UncertaintyUncertain key program variables have led analysts to exclude a program from valuation models, limiting the asset’s current contribution to company value until clinical and development details are clarified.
Atai Beckley N.V. News
ATAI FAQ
What was Atai Beckley N.V.’s price range in the past 12 months?
Atai Beckley N.V. lowest stock price was $1.15 and its highest was $6.75 in the past 12 months.
What is Atai Beckley N.V.’s market cap?
Atai Beckley N.V.’s market cap is $1.34B.
When is Atai Beckley N.V.’s upcoming earnings report date?
Atai Beckley N.V.’s upcoming earnings report date is Mar 26, 2026 which is in 21 days.
How were Atai Beckley N.V.’s earnings last quarter?
Atai Beckley N.V. released its earnings results on Nov 12, 2025. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.115 by -$0.165.
Is Atai Beckley N.V. overvalued?
According to Wall Street analysts Atai Beckley N.V.’s price is currently Undervalued.
Does Atai Beckley N.V. pay dividends?
Atai Beckley N.V. pays a Notavailable dividend of $6 which represents an annual dividend yield of N/A. See more information on Atai Beckley N.V. dividends here
What is Atai Beckley N.V.’s EPS estimate?
Atai Beckley N.V.’s EPS estimate is -0.11.
How many shares outstanding does Atai Beckley N.V. have?
Atai Beckley N.V. has 363,214,600 shares outstanding.
What happened to Atai Beckley N.V.’s price movement after its last earnings report?
Atai Beckley N.V. reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.115. Following the earnings report the stock price went down -2.257%.
Which hedge fund is a major shareholder of Atai Beckley N.V.?
Currently, no hedge funds are holding shares in ATAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atai Beckley N.V. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.71 (298.64% Upside)
$14.71 (298.64% Upside)
Blogger Sentiment
Bullish
ATAI Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 941.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $154.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Negative
20 days / 200 days
Momentum
146.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.42%
Trailing 12-Months
Company Description
Atai Beckley N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
ATAI Stock 12 Month Forecast
Average Price Target
$14.71
▲(298.64% Upside)
Technical Analysis
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
―
Praxis Precision Medicines
―
Ownership Overview
23.34% Insiders
0.62% Mutual Funds
1.06% Other Institutional Investors
72.90% Public Companies and Individual Investors